~~<i id='328FAD0230'><strike id='328FAD0230'><tt id='328FAD0230'><pre id='328FAD0230'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：entertainment 2025-09-28 00:48:48 - browse：9

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： 2 million sign

hotspot

entertainment

hotspot

explore

ScientificwatchdogsSholtoDavid(right)andElisabethBikjoinSTAT'sJonathenWosenattheSTATBreakthroughSumm

WSS

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Princess Kate attends Wimbledon with Roger Federer: See the photos

Glen Campbell's doctor discusses his public struggle with Alzheimer's

entertainment

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

The leaders of Italy and Poland say European Union should focus on stopping migration

Duchenne breakthrough therapy leaves behind pioneering families

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Psychedelics group wrestles with new pharma identity

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Apple is now the first public company to be valued at $3 trillion

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

23andMe had bad news about my health. I wish a person had delivered it

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

entertainment

Glen Campbell's doctor discusses his public struggle with Alzheimer's

2 million sign

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

A bus careens into a gulch in southern Mexico, leaving 27 people dead

EU moves toward latest gene techniques in food production to counter climate change, shortages

China dismisses criticism of top diplomat's comments appearing to push for race

hotspot

hotspot

hotspot

explore